1 of 1
Story summary
- Pfizer Inc.'s mRNA flu vaccine showed superior effectiveness in a Phase 3 trial of 18,000 adults during 2022-2023.
- The trial showed a 34.5% reduction in flu-like illnesses, with 57 cases in the mRNA group and 87 in the traditional group.
- Side effects were more common with the mRNA vaccine, including a higher fever.
- Experts say approval may face skepticism toward mRNA technology, from officials such as Robert F. Kennedy Jr.
